Menu
Recruiting NCT06061627

A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD

No phase Interventional Heart Failure Intraventricular Block

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: LOT-CRT group, BiVP group.
Who it may be relevant to
Registry conditions: Heart Failure, Intraventricular Block. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomized Controlled Trial of Left Bundle brAnch opTimized Cardiac Resynchronization Therapy Versus conventionaL Bi-vEntricular Pacing in Heart Failure Patients With Nonspecific Intraventricular Conduction Delay

Overview

BATTLE study has been designed as a prospective, multi-center, randomized, controlled trial. This study will enroll 83 patients with chronic heart failure accompanied by intraventricular block (NICD) over an estimated recruitment period of 3 years. An LOT-CRT group will be compared with a group of conventional BiVP in the follow-up of at least 6 months. The study aimed to compare the curative effect of LOT-CRT in preserving LV systolic function with traditional BiVP in chronic heart failure patients with NICD.

Detailed description

Cardiac resynchronization therapy is a standardized treatment strategy for patients with chronic heart failure complicated by wide QRS waves. With the continuous development of physiological pacing technology, traditional cardiac resynchronization therapy, namely biventricular pacing technology, is constantly challenged. Left bundle branch area pacing (LBBAP), as the main method of physiological pacing technology, is currently increasingly widely used in clinical practice. In recent years, research has mainly focused on heart failure patients with wide QRS waves such as non ischemic cardiomyopathy and typical left bundle branch block (LBBB). The recently published LBBP-RESYNC study was a randomized controlled study comparing left bundle branch pacing (LBBP) and biventricular pacing. The results showed that LBBP can achieve better improvement in left ventricular function compared to traditional biventricular pacing.

Compared with patients with typical LBBB, traditional biventricular pacing synchronized treatment is less effective in chronic heart failure patients accompanied by intraventricular block (NICD), which is closely related to the electrophysiological mechanism of LBBB. The blocking site of typical LBBB is generally located within the His bundle to the proximal end of the left bundle branch, while the distal end of the left bundle branch is relatively healthy. Therefore, LBBP can completely correct this type of LBBB and significantly narrow the QRS wave; The electrophysiological mechanism of NICD is relatively complex, and there may be multiple blocking sites, and LBBP cannot be completely corrected. How to improve the treatment efficacy and clinical prognosis of chronic heart failure patients with NICD is an important scientific issue that urgently needs to be solved. It is unclear whether left bundle branch pacing technology can provide support for cardiac function in such patients.

Traditional biventricular pacing combines right ventricular and left epicardial pacing; LBBAP combined with left ventricular epicardial pacing, also known as LOT-CRT, is an innovative pacing method. This study aims to explore the application value of LBBAP in patients with chronic heart failure and NICD.

Interventions

  • Procedure LOT-CRT group
    In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads LBBAP includes LBBP and LVSP. LBBP is defined if fulfilling criterion 1 and at least one in criteria 2: 1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs); 2. One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms: 1. Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and Q
  • Procedure BiVP group
    Implantation of a LV pacing lead is attempted using the standard-of-care technique first.

Primary outcome measures

  • Left ventricular ejection fraction(LVEF) [Time frame: Baseline; 6-month follow-up]
Secondary outcome measures (12)
  • Paced QRS duration [Time frame: Postoperative day 1; 1-month,3-month and 6-month follow-up]
  • A combined clinical endpoint of all-cause mortality and heart failure hospitalization, [Time frame: 6-month follow-up]
  • Left ventricular end systolic volume(LVESV) [Time frame: Baseline; 3-month, 6-month follow-up]
  • Left ventricular end diastolic volume(LVEDV) [Time frame: Baseline; 3-month, 6-month follow-up]
  • Left ventricular end systolic diameter(LVESD) [Time frame: Baseline; 3-month, 6-month follow-up]
  • Left ventricular end diastolic diameter(LVEDD) [Time frame: Baseline; 3-month, 6-month follow-up]
  • Change in Quality Of Life Questionnaire score between baseline and follow-up [Time frame: Baseline; 3-month, 6-month follow-up]
  • Changes in New York Heart Association Heart Function Classification between baseline and follow-up [Time frame: Baseline; 3-month, 6-month follow-up]
  • Changes in 6-minute Walk Distance between baseline and follow-up [Time frame: Baseline; 3-month, 6-month follow-up]
  • Changes in concentration of NT-proBNP in blood between baseline and follow-up [Time frame: Baseline; 3-month, 6-month follow-up]
  • Incidence of stroke events [Time frame: 6-month follow-up]
  • A combined arrhythmia endpoint of new-onset atrial fibrillation and malignant ventricular arrhythmia [Time frame: 6-month follow-up]

Eligibility criteria

Inclusion criteria

  • Ischemic or non ischemic cardiomyopathy
  • Optimal medical therapy for at lest 3 months
  • NYHA class II-IV
  • LVEF≤35% as assessed by echocardiography
  • Sinus rhythm (may have paroxysmal atrial fibrillation)
  • QRS duration ≥ 150ms
  • Intraventricular block (NICD), QRS morphology is neither LBBB nor RBBB

Exclusion criteria

  • Valvular heart disease that requires or has undergone surgical intervention
  • After mechanical tricuspid valve replacement
  • Persistent or permanent atrial fibrillation or atrial flutter
  • Second or third degree atrioventricular block
  • Have a history of acute myocardial infarction within 3 months prior to enrollment
  • Patient's expected survival time is less than 12 months
  • Pregnant or planned to conceive
  • Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)
  • Patients with simple and persistent left superior vena cava
  • Patients with existing pacemaker implantation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

China · 1 center
  • The First Affiliated Hospital with Nanjing Medical University — Nanjing

Publications

  • Wang Y, Zhu H, Hou X, Wang Z, Zou F, Qian Z, Wei Y, Wang X, Zhang L, Li X, Liu Z, Xue S, Qin C, Zeng J, Li H, Wu H, Ma H, Ellenbogen KA, Gold MR, Fan X, Zou J; LBBP-RESYNC Investigators. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 Sep 27;80(13):1205-1216. doi: 10.1016/j.jacc.2022.07.019. PMID 36137670
  • Jastrzebski M, Moskal P, Huybrechts W, Curila K, Sreekumar P, Rademakers LM, Ponnusamy SS, Herweg B, Sharma PS, Bednarek A, Rajzer M, Vijayaraman P. Left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT): Results from an international LBBAP collaborative study group. Heart Rhythm. 2022 Jan;19(1):13-21. doi: 10.1016/j.hrthm.2021.07.057. Epub 2021 Jul 30. PMID 34339851

Identifiers

NCT: NCT06061627 · FirstNanjingMU005

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗